Navigation Links
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Date:7/22/2009

ug. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding timing, progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer H
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
3. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
6. Promising drug combination may help those with ocular melanoma that has spread
7. Combination therapy reverses effects of portal hypertension in rats
8. Combination vaccines okay for infants, study shows
9. Antidepressants and painkillers - a dangerous combination
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... Raton, FL (PRWEB) May 19, 2013 ... launched the website YazSideEffects.com in a concerted effort to ... of the combination birth control drugs Yaz, Yasmin & ... offers a wealth of information on the notorious birth ... lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin & ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... and the good fats in Omega-3 fatty acids help new ... the issue of the International Breastfeeding Journal. ... affecting anywhere from 10 percent to 20 percent of postpartum ... as high as 40 percent or 50 percent. Since depression ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... New Jersey The nations publicized gay governor, James E. McGreevy ... he has managed to be in the news for ... and has become an Episcopalian. ,Former Gov. James E. ... officially inducted into the Episcopal religion on Sunday at St. ...
... here have developed a device that can enable the blind to ... it costs Rs.2,000-3,000 and it reads texts through an embedded system ... ,Right now it can only read text, but ... ,The Agra College team that took six months to ...
... to the information furnished by Indira Gandhi National Open ... of Parliament/State legislature or deemed to be university ... of norms and guidelines laid down by the Distance ... its meeting held on March 23, 2007 had resolved ...
... state representatives from 105 countries met Friday to formally adopt ... impacts of global warming after five days of heated debate ... discussions ended at 3:30 a.m. Friday," said Carloa Traverso Saibante, ... (IPCC). ,Once the IPCC report is formally adopted, ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
(Date:5/17/2013)... today announced that it will report its 2013 first quarter earnings on ... Ed Borkowski , CFO, will host an analyst and ... To participate in the conference call within the U.S. and ... conference call outside the U.S. and Canada , dial ... Participants should dial in 10 minutes prior to the start of the ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... Male Hypogonadism, LEXINGTON, Mass., Aug. 28 ... that it has submitted,a New Drug Application (NDA) ... approval for NEBIDO(R) (testosterone undecanoate) intramuscular,injection, a long-acting ... and secondary hypogonadism. Each 1000 mg injection of,NEBIDO ...
... Corporation,(Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen ... dosing in a Phase I/II clinical,trial evaluating belinostat ... the anthracycline idarubicin for the,treatment of Acute Myeloid ... sites in the European Union. Patients under ...
Cached Medicine Technology:Indevus Announces Submission of New Drug Application 2Indevus Announces Submission of New Drug Application 3Indevus Announces Submission of New Drug Application 4Indevus Announces Submission of New Drug Application 5Indevus Announces Submission of New Drug Application 6CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6
... Revolutions start with small things. The ... one of the trailblazers of the ... the,trend towards ever smaller access and ... operation site. ,The HiLAN XS motor ...
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
... The basic frame, consisting of one part only, ... fixations of highly compressed Polyamide may be rotated ... to all head sizes and shapes, as well. ... frame far enough in caudal direction, which is ...
Medicine Products: